What is CorePharma?
CorePharma LLC is a pharmaceutical entity established in 1998, dedicated to the development and manufacturing of both branded and generic pharmaceuticals across a spectrum of therapeutic areas. The company operates advanced facilities for product development, contract manufacturing, and analytical testing, with an annual production capacity exceeding 2 billion units, particularly in oral solid dosages. CorePharma's operational ethos is built on quality, integrity, and teamwork, positioning it as a reliable partner for pharmaceutical industry clients seeking compliant and efficient manufacturing solutions.
How much funding has CorePharma raised?
CorePharma has raised a total of $1.1M across 2 funding rounds:
Debt
$350K
Debt
$780K
Debt (2020): $350K with participation from PPP
Debt (2021): $780K led by PPP
Key Investors in CorePharma
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for CorePharma?
The recent major strategic investment indicates a phase of accelerated scaling or expansion for CorePharma. This capital infusion is likely to fuel advancements in its product pipeline, enhance manufacturing capabilities, or support market penetration strategies. Given the enterprise-level context of its total funding, CorePharma appears poised for significant growth and further consolidation within the competitive pharmaceutical landscape, potentially exploring new therapeutic areas or expanding its contract manufacturing services.
See full CorePharma company page
